


MER- MEDICAL EXAMINATION REPORT

Date of Examination	25/11/2023		
NAME	Ranbhari Gajani		
AGE	33	Gender	Male
HEIGHT(cm)	168	WEIGHT (kg)	63
B.P.	110/80		
ECG	Normal		
X Ray	Normal		
Vision Checkup	Color Vision :		
	Far Vision Ratio :		
	Near Vision Ratio :		
Present Ailments	No		
Details of Past ailments (If Any)	No		
Comments / Advice : She /He is Physically Fit			


Dr. Vipul Chavda
 MD (Internal Medicine)
 Signature with Stamp of Medical Examiner



NAME :	GOSAI PARTHGIRI	DATE :	25/11/2023
AGE/SEX:	33Y/M	REG.NO :	00
REFERRED BY: HEALTH CHECK UP			

X-RAY CHEST PA VIEW

- Both lung fields are clear.
- No evidence of consolidation or Koch's lesion seen.
- Heart size is within normal limit.
- Both CP angles are clear.
- Both dome of diaphragm appear normal.
- Bony thorax under vision appears normal.

Dr. VIDHI SHAH
MD RADIODIAGNOSIS



NAME	Gosai Parthgiri		
AGE/ SEX	33Y/ M	DATE	25 th Nov 2023
REF. BY	HC	DONE BY	Dr Parth Thakkar

2D ECHO CARDIOGRAPHY & COLOR DOPPLER STUDY

FINDINGS:-

- Normal LV systolic function, LVEF=60%.
- No RWMA at rest
- Normal LV Compliance.
- LV & LA are of normal size.
- RA & RV are of normal size.
- All valves are structurally normal.
- Intact IAS & IVS.
- Trivial MR, No AR, No PR.
- Trivial TR, No PAH, RVSP 30mmHg
- No Clots or vegetation.
- No pericardial effusion.
- IVC is normal, shows normal respiratory variation

MEASUREMENTS:-


LVIDD	46(mm)	LA	34 (mm)
LVIDS	27 (mm)	AO	29 (mm)
LVEF	60%	AV cusp	
IVSD / LVPWD	10/10 (mm)	EPSS	

DOPPLER STUDY:-

Valve	Velocity (M/sec)	Max gradient (MmHg)	Mean gradient (Mm Hg)	Valve area Cm ²
Aortic	1.1	5		
Mitral	0.5/0.7			
Pulmonary	0.8	3.0		
Tricuspid	2.1	25		

CONCLUSION:-

- Normal LV systolic function, LVEF=60%.
- No RWMA at rest
- Normal LV Compliance.
- All valves are structurally normal.
- Trivial MR, No AR, No PR.
- Trivial TR, No PAH. RVSP 30mmHg
- IVC normal



DR. PARTH THAKKAR
 MD (Med.), DrNB (Cardiology)
 Interventional Cardiologist
 7990179258

Concept Diagnostics

1378 / GOSAI PARTHGIRI / 33 Yrs / M / 168Cms. / 63Kgs. / Smoker

Heart Rate : 69 bpm / Tested On : 25-Nov-23 15:18:13 / HF 0.05 Hz - LF 35 Hz / Notch 50 Hz / Sn 1.00 Cm/mV / Sw 25 mm/s

ECG



Naval

Reported By: DR PARTH THAKKAR

NAME :	GOSAI PARTHGIRI	DATE :	25/11/2023
AGE/SEX:	33Y/M	REG.NO :	00
REFERRED BY: HEALTH CHECK UP			

USG ABDOMEN

LIVER: normal in size & shows normal echotexture. No evidence of dilated IHBR. No evidence of focal or diffuse lesion. CBD & Portal vein appears normal.

GALL-BLADDER: normal, No evidence of Gall Bladder calculi.

PANCREAS: appears normal in size & echotexture, No evidence of peri-pancreatic fluid collection.

SPLEEN: normal in size & shows normal echogenicity.

KIDNEYS: Right kidney measures 89 x 43 mm. Left kidney measures 93 x 46 mm. Both kidneys appear normal in size & echotexture. No evidence of calculus or hydronephrosis on either side.

URINARY BLADDER: appears normal and shows normal distension & normal wall thickness. No evidence of calculus or mass lesion.

PROSTATE: normal in size & echotexture.

No evidence of Ascites.


No evidence of significant lymphadenopathy.

USG WITH HIGH FREQUENCY SOFT TISSUE PROBE:

Visualized bowel loops appears normal in caliber. No evidence of focal or diffuse wall thickening. No collection in RIF.




CONCLUSION:

➤ Normal USG abdomen.



Dr. VIDHI SHAH
MD RADIODIAGNOSIS





TEST REPORT

Reg. No. : 311100475	Reg. Date : 25-Nov-2023 09:02	Ref.No :	Approved On : 25-Nov-2023 10:21
Name : Mr. PARTH GOSAI			Collected On : 25-Nov-2023 09:29
Age : 33 Years	Gender: Male	Pass. No. :	Dispatch At :
Ref. By : APOLLO			Tele No. :
Location :			

Test Name	Results	Units	Bio. Ref. Interval
Complete Blood Count			
<u>Specimen: EDTA blood</u>			
Hemoglobin			
Hemoglobin(SLS method)	14.7	g/dL	13.0 - 17.0
Hematocrit (calculated)	41.1	%	40 - 50
RBC Count(Ele.Impedence)	5.09	X 10 ¹² /L	4.5 - 5.5
MCV (Calculated)	L 80.7	fL	83 - 101
MCH (Calculated)	28.9	pg	27 - 32
MCHC (Calculated)	H 35.8	g/dL	31.5 - 34.5
RDW (Calculated)	13.9	%	11.5 - 14.5
Differential WBC count (Impedance and flow)			
Total WBC count	6600	/μL	4000 - 10000
Neutrophils	50	%	38 - 70
Lymphocytes	43	%	21 - 49
Monocytes	04	%	3 - 11
Eosinophils	03	%	0 - 7
Basophils	00		
Platelet			
Platelet Count (Ele.Impedence)	214000	/cmm	150000 - 410000
MPV	9.20	fL	6.5 - 12.0
EDTA Whole Blood			

Note: All abnormal hemograms are reviewed and confirmed microscopically. Peripheral blood smear and malarial parasite examination are not part of CBC report.

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Swati Shah

M.B.D.C.P.
G-5456

Page 1 of 15

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 10:21

TEST REPORT

Reg. No. : 311100475 Reg. Date : 25-Nov-2023 09:02 Ref.No : Approved On : 25-Nov-2023 12:38
Name : Mr. PARTH GOSAI Collected On : 25-Nov-2023 09:29
Age : 33 Years Gender: Male Pass. No. : Dispatch At :
Ref. By : APOLLO Tele No. :
Location :

Test Name	Results	Units	Bio. Ref. Interval
ESR	4	mm/hr	17-50 Yrs : <12, 51-60 Yrs : <19, 61-70 Yrs : <20, >70 Yrs : <30

Capillary Microphotometry

Sample Type: EDTA Whole Blood

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Avinash B Panchal

MBBS,DCP
G-44623

Page 2 of 15

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 12:38

TEST REPORT

Reg. No. : 311100475 Reg. Date : 25-Nov-2023 09:02 Ref.No : Approved On : 25-Nov-2023 10:53
Name : Mr. PARTH GOSAI Collected On : 25-Nov-2023 09:29
Age : 33 Years Gender: Male Pass. No. : Dispatch At :
Ref. By : APOLLO Tele No. :
Location :

Test Name	Results	Units	Bio. Ref. Interval
BLOODGROUP & RH			
<u>Specimen: EDTA and Serum; Method: Gel card system</u>			
Blood Group "ABO" <i>Agglutination</i>	"A"		
Blood Group "Rh" <i>Agglutination</i>	Positive		
EDTA Whole Blood			

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Swati Shah

M.B.D.C.P.
G-5456

Page 3 of 15

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 10:53

TEST REPORT

Reg. No. : 311100475 Reg. Date : 25-Nov-2023 09:02 Ref.No : Approved On : 25-Nov-2023 11:18
Name : Mr. PARTH GOSAI Collected On : 25-Nov-2023 09:29
Age : 33 Years Gender: Male Pass. No. : Dispatch At :
Ref. By : APOLLO Tele No. :
Location :

Test Name	Results	Units	Bio. Ref. Interval
FASTING PLASMA GLUCOSE Specimen: Fluoride plasma			
Fasting Plasma Glucose <i>Hexokinase</i>	81.90	mg/dL	Normal: <=99.0 Prediabetes: 100-125 Diabetes :>=126

Flouride Plasma

Criteria for the diagnosis of diabetes:

1. HbA1c >= 6.5 *

Or

2. Fasting plasma glucose >126 gm/dL. Fasting is defined as no caloric intake at least for 8 hrs.

Or

3. Two hour plasma glucose >= 200mg/dL during an oral glucose tolerance test by using a glucose load containing equivalent of 75 gm anhydrous glucose dissolved in water.

Or

4. In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose >= 200 mg/dL. *In the absence of unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing. American diabetes association. Standards of medical care in diabetes 2011. Diabetes care 2011;34;S11.

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Swati Shah

M.B.D.C.P.
G-5456

Page 4 of 15

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 11:18

TEST REPORT

Reg. No. : 311100475 Reg. Date : 25-Nov-2023 09:02 Ref.No : Approved On : 25-Nov-2023 15:05
Name : Mr. PARTH GOSAI Collected On : 25-Nov-2023 13:10
Age : 33 Years Gender: Male Pass. No. : Dispatch At :
Ref. By : APOLLO Tele No. :
Location :

Test Name	Results	Units	Bio. Ref. Interval
POST PRANDIAL PLASMA GLUCOSE Specimen: Fluoride plasma			
Post Prandial Plasma Glucose <i>Hexokinase</i>	L 92.45	mg/dL	Normal: <=139 Prediabetes : 140-199 Diabetes: >=200
Flouride Plasma			

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Keyur Patel

M.B.B.S.,D.C.P(Patho) Page 5 of 15
G- 22475

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 15:05

TEST REPORT

Reg. No. : 311100475 Reg. Date : 25-Nov-2023 09:02 Ref.No : Approved On : 25-Nov-2023 12:04
Name : Mr. PARTH GOSAI Collected On : 25-Nov-2023 09:29
Age : 33 Years Gender: Male Pass. No. : Dispatch At :
Ref. By : APOLLO Tele No. :
Location :

Test Name	Results	Units	Bio. Ref. Interval
GGT	19.0	U/L	10 - 71
<i>L-Y-Glutamyl-3 Carboxy-4-Nitroanilide, Enzymetic Colorimetric</i>			
Serum			

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Swati Shah

M.B.D.C.P.
G-5456

Page 6 of 15

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 12:04

TEST REPORT

Reg. No. : 311100475	Reg. Date : 25-Nov-2023 09:02	Ref.No. :	Approved On : 25-Nov-2023 11:04
Name : Mr. PARTH GOSAI			Collected On : 25-Nov-2023 09:29
Age : 33 Years	Gender: Male	Pass. No. :	Dispatch At :
Ref. By : APOLLO			Tele No. :
Location :			

Test Name	Results	Units	Bio. Ref. Interval
LIPID PROFILE			
CHOLESTEROL	184.00	mg/dL	Desirable <=200 Borderline high risk 200 - 240 High Risk >240
Triglyceride <i>Enzymatic Colorimetric Method</i>	104.00	mg/dL	<150 : Normal, 150-199 : Border Line High, 200-499 : High, >=500 : Very High
Very Low Density Lipoprotein(VLDL) <i>Calculated</i>	21	mg/dL	0 - 30
Low-Density Lipoprotein (LDL) <i>Calculated Method</i>	116.77	mg/dL	< 100 : Optimal, 100-129 : Near Optimal/above optimal, 130-159 : Borderline High, 160-189 : High, >=190 : Very High
High-Density Lipoprotein(HDL)	46.23	mg/dL	<40 >60
CHOL/HDL RATIO <i>Calculated</i>	H 3.98		0.0 - 3.5
LDL/HDL RATIO <i>Calculated</i>	2.53		1.0 - 3.4
TOTAL LIPID <i>Calculated</i>	536.00	mg/dL	400 - 1000
Serum			

As a routine test to determine if your cholesterol level is normal or falls into a borderline-, intermediate- or high-risk category.
 To monitor your cholesterol level if you had abnormal results on a previous test or if you have other risk factors for heart disease.
 To monitor your body's response to treatment, such as cholesterol medications or lifestyle changes.
 To help diagnose other medical conditions, such as liver disease.
 Note : biological reference intervals are according to the national cholesterol education program (NCEP) guidelines.

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Swati Shah

M.B.D.C.P.
G-5456

Page 7 of 15

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 11:04

TEST REPORT

Reg. No. : 311100475	Reg. Date : 25-Nov-2023 09:02	Ref.No :	Approved On : 25-Nov-2023 11:03
Name : Mr. PARTH GOSAI			Collected On : 25-Nov-2023 09:29
Age : 33 Years	Gender : Male	Pass. No. :	Dispatch At :
Ref. By : APOLLO			Tele No. :
Location :			

Test Name	Results	Units	Bio. Ref. Interval
<u>LIVER FUNCTION TEST</u>			
TOTAL PROTEIN	6.90	g/dL	6.6 - 8.8
ALBUMIN	4.89	g/dL	3.5 - 5.2
GLOBULIN <i>Calculated</i>	L 2.01	g/dL	2.4 - 3.5
ALB/GLB <i>Calculated</i>	H 2.43		1.2 - 2.2
SGOT	23.20	U/L	<35
SGPT	25.30	U/L	<41
Alkaline Phosphatase <i>ENZYMATIC COLORIMETRIC IFCC, PNP, AMP BUFFER</i>	60.00	U/L	40 - 130
TOTAL BILIRUBIN	0.83	mg/dL	0.1 - 1.2
DIRECT BILIRUBIN	0.23	mg/dL	<0.2
INDIRECT BILIRUBIN <i>Calculated</i>	0.60	mg/dL	0.0 - 1.00
Serum			

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Swati Shah

M.B.D.C.P.
G-5456

Page 8 of 15

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 11:03

TEST REPORT

Reg. No. : 311100475 **Reg. Date :** 25-Nov-2023 09:02 **Ref.No :** **Approved On :** 25-Nov-2023 17:04
Name : Mr. PARTH GOSAI **Collected On :** 25-Nov-2023 09:29
Age : 33 Years **Gender:** Male **Pass. No. :** **Dispatch At :**
Ref. By : APOLLO **Tele No. :**
Location :

Test Name	Results	Units	Bio. Ref. Interval
HEMOGLOBIN A1C (HBA1C) <i>High Performance Liquid Chromatography (HPLC)</i>	5.1	%	Normal: <= 5.6 Prediabetes: 5.7-6.4 Diabetes: >= 6.5 6-7 : Near Normal Glycemia, <7 : Goal , 7-8 : Good Control ,>8 : Action Suggested.
Mean Blood Glucose <i>(Calculated)</i>	100	mg/dL	

Sample Type: EDTA Whole Blood

Criteria for the diagnosis of diabetes

- HbA1c ≥ 6.5 * Or Fasting plasma glucose >126 gm/dL. Fasting is defined as no caloric intake at least for 8 hrs. Or
- Two hour plasma glucose ≥ 200 mg/dL during an oral glucose tolerance test by using a glucose load containing equivalent of 75 gm anhydrous glucose dissolved in water. Or
- In a patient with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose ≥ 200 mg/dL. *In the absence of unequivocal hyperglycemia, criteria 1-3 should be confirmed by repeat testing. American diabetes association. Standards of medical care in diabetes 2011. Diabetes care 2011;34:S11.

Limitation of HbA1c

- In patients with Hb variants even analytically correct results do not reflect the same level of glycemic control that would be expected in patients with normal population.
- Any cause of shortened erythrocyte survival or decreased mean erythrocyte survival or decreased mean erythrocyte age eg. hemolytic diseases, pregnancy, significant recent/chronic blood loss etc. will reduce exposure of RBC to glucose with consequent decrease in HbA1c values.
- Glycated HbF is not detected by this assay and hence specimens containing high HbF ($>10\%$) may result in lower HbA1c values than expected. Importance of HbA1C (Glycated Hb.) in Diabetes Mellitus

- HbA1C, also known as glycated hemoglobin, is the most important test for the assessment of long term blood glucose control(also called glycemic control).
 - HbA1C reflects mean glucose concentration over past 6-8 weeks and provides a much better indication of long term glycemic control than blood glucose determination.
 - HbA1c is formed by non-enzymatic reaction between glucose and Hb. This reaction is irreversible and therefore remains unaffected by short term fluctuations in blood glucose levels.
 - Long term complications of diabetes such as retinopathy (Eye-complications), nephropathy (kidney-complications) and neuropathy (nerve complications), are potentially serious and can lead to blindness, kidney failure, etc.
 - Glycemic control monitored by HbA1c measurement using HPLC method (GOLD STANDARD) is considered most important. (Ref. National Glycohemoglobin Standardization Program - NGSP)

Note : Biological reference intervals are according to American Diabetes Association (ADA) Guidelines.

Test done from collected sample.

This is an electronically authenticated report.



Approved by: **Dr. Hiral Arora**

M.D. Biochemistry Page 9 of 15
 Reg. No.: G-32999

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 17:04

TEST REPORT

Reg. No. : 311100475	Reg. Date : 25-Nov-2023 09:02	Ref.No :	Approved On : 25-Nov-2023 17:04
Name : Mr. PARTH GOSAI			Collected On : 25-Nov-2023 09:29
Age : 33 Years	Gender: Male	Pass. No. :	Dispatch At :
Ref. By : APOLLO			Tele No. :
Location :			

Bio-Rad CDM System
Bio-Rad Variant V-II Instrument #1

PATIENT REPORT
V2TURBO_A1c_2.0

Patient Data

Sample ID: 131103500345
 Patient ID:
 Name:
 Physician:
 Sex:
 DOB:

Analysis Data


Analysis Performed: 25/11/2023 15:35:49
 Injection Number: 5384+
 Run Number: 227
 Rack ID:
 Tube Number: 8
 Report Generated: 25/11/2023 15:53:57
 Operator ID:

Comments:

Peak Name	NGSP %	Area %	Retention Time (min)	Peak Area
A1a	---	1.3	0.167	20549
A1b	---	0.7	0.245	11379
F	---	0.6	0.296	9241
Unknown	---	0.1	0.383	2274
LA1c	---	1.6	0.455	25051
A1c	5.1	---	0.579	60759
P3	---	3.4	0.833	54720
P4	---	1.2	0.908	19588
Ao	---	87.3	1.030	1403849

Total Area: 1,607,411

HbA1c (NGSP) = 5.1 %



Test done from collected sample.

This is an electronically authenticated report.



Approved by: *Hiral Arora*
Dr. Hiral Arora

M.D. Biochemistry Page 10 of 15
Reg. No.: G-32999

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 17:04

TEST REPORT

Reg. No. : 311100475 **Reg. Date :** 25-Nov-2023 09:02 **Ref.No :** **Approved On :** 25-Nov-2023 13:28
Name : Mr. PARTH GOSAI **Collected On :** 25-Nov-2023 09:29
Age : 33 Years **Gender:** Male **Pass. No. :** **Dispatch At :**
Ref. By : APOLLO **Tele No. :**
Location :

Test Name	Results	Units	Bio. Ref. Interval
THYROID FUNCTION TEST			
T3 (triiodothyronine), Total <small>CMIA</small>	1.13	ng/mL	0.70 - 2.04
T4 (Thyroxine), Total <small>CMIA</small>	8.94	µg/dL	4.6 - 10.5
TSH (Thyroid stimulating hormone) <small>CMIA</small>	3.537	µIU/mL	0.35 - 4.94

Sample Type: Serum

Comments:

Thyroid stimulating hormone (TSH) is synthesized and secreted by the anterior pituitary in response to a negative feedback mechanism involving concentrations of FT3 (free T3) and FT4 (free T4). Additionally, the hypothalamic tripeptide, thyrotropin-releasing hormone (TRH), directly stimulates TSH production. TSH stimulates thyroid cell production and hypertrophy, also stimulate the thyroid gland to synthesize and secrete T3 and T4. Quantification of TSH is significant to differentiate primary (thyroid) from secondary (pituitary) and tertiary (hypothalamus) hypothyroidism. In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low.

TSH levels During Pregnancy :

- First Trimester : 0.1 to 2.5 µIU/mL
- Second Trimester : 0.2 to 3.0 µIU/mL
- Third trimester : 0.3 to 3.0 µIU/mL

Reference : Carl A.Burtis,Edward R.Ashwood,David E.Bruns. Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. 5th Edition. Philadelphia: WB Saunders,2012:2170

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Avani Patel

M.D. Biochemistry Page 11 of 15
Reg No.- G-34103

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 13:28

TEST REPORT

Reg. No. : 311100475	Reg. Date : 25-Nov-2023 09:02	Ref.No :	Approved On : 25-Nov-2023 12:06
Name : Mr. PARTH GOSAI			Collected On : 25-Nov-2023 09:29
Age : 33 Years	Gender: Male	Pass. No. :	Dispatch At :
Ref. By : APOLLO			Tele No. :
Location :			

Test Name	Results	Units	Bio. Ref. Interval
<u>URINE ROUTINE EXAMINATION</u>			
<u>Physical Examination</u>			
Colour	Pale Yellow		
Clarity	Clear		
<u>CHEMICAL EXAMINATION (by strip test)</u>			
pH	6.0		4.6 - 8.0
Sp. Gravity	1.015		1.002 - 1.030
Protein	Nil		Absent
Glucose	Nil		Absent
Ketone	Nil		Absent
Bilirubin	Nil		Nil
Nitrite	Negative		Nil
Leucocytes	Nil		Nil
Blood	Absent		Absent
<u>MICROSCOPIC EXAMINATION</u>			
Leucocytes (Pus Cells)	Nil		0 - 5/hpf
Erythrocytes (RBC)	Nil		0 - 5/hpf
Casts	Nil	/hpf	Absent
Crystals	Nil		Absent
Epithelial Cells	Nil		Nil
Monilia	Nil		Nil
T. Vaginalis	Nil		Nil
Urine			

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Swati Shah

M.B.D.C.P.
G-5456

Page 12 of 15

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 12:06

TEST REPORT

Reg. No. : 311100475 Reg. Date : 25-Nov-2023 09:02 Ref.No : Approved On : 25-Nov-2023 11:03
Name : Mr. PARTH GOSAI Collected On : 25-Nov-2023 09:29
Age : 33 Years Gender: Male Pass. No. : Dispatch At :
Ref. By : APOLLO Tele No. :
Location :

Test Name	Results	Units	Bio. Ref. Interval
Creatinine	1.16	mg/dL	0.67 - 1.5

Serum

Creatinine is the most common test to assess kidney function. Creatinine levels are converted to reflect kidney function by factoring in age and gender to produce the eGFR (estimated Glomerular Filtration Rate). As the kidney function diminishes, the creatinine level increases; the eGFR will decrease. Creatinine is formed from the metabolism of creatine and phosphocreatine, both of which are principally found in muscle. Thus the amount of creatinine produced is, in large part, dependent upon the individual's muscle mass and tends not to fluctuate much from day-to-day. Creatinine is not protein bound and is freely filtered by glomeruli. All of the filtered creatinine is excreted in the urine.

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Swati Shah

M.B.D.C.P.
G-5456

Page 13 of 15

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 11:03

TEST REPORT

Reg. No. : 311100475	Reg. Date : 25-Nov-2023 09:02	Ref.No :	Approved On : 25-Nov-2023 11:03
Name : Mr. PARTH GOSAI			Collected On : 25-Nov-2023 09:29
Age : 33 Years	Gender: Male	Pass. No. :	Dispatch At :
Ref. By : APOLLO			Tele No. :
Location :			

Test Name	Results	Units	Bio. Ref. Interval
Urea	19.4	mg/dL	17 - 43

Serum

Useful screening test for evaluation of kidney function. Urea is the final degradation product of protein and amino acid metabolism. In protein catabolism, the proteins are broken down to amino acids and deaminated. The ammonia formed in this process is synthesized to urea in the liver. This is the most important catabolic pathway for eliminating excess nitrogen in the human body. Increased blood urea nitrogen (BUN) may be due to prerenal causes (cardiac decompensation, water depletion due to decreased intake and excessive loss, increased protein catabolism, and high protein diet), renal causes (acute glomerulonephritis, chronic nephritis, polycystic kidney disease, nephrosclerosis, and tubular necrosis), and postrenal causes (eg, all types of obstruction of the urinary tract, such as stones, enlarged prostate gland, tumors). The determination of serum BUN currently is the most widely used screening test for the evaluation of kidney function. The test is frequently requested along with the serum creatinine test since simultaneous determination of these 2 compounds appears to aid in the differential diagnosis of prerenal, renal and postrenal hyperuremia.

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Swati Shah

M.B.D.C.P.
G-5456

Page 14 of 15

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 11:03

TEST REPORT

Reg. No. : 311100475	Reg. Date : 25-Nov-2023 09:02	Ref.No :	Approved On : 25-Nov-2023 10:21
Name : Mr. PARTH GOSAI			Collected On : 25-Nov-2023 09:29
Age : 33 Years	Gender: Male	Pass. No. :	Dispatch At :
Ref. By : APOLLO			Tele No. :
Location :			

Test Name	Results	Units	Bio. Ref. Interval
<u>ELECTROLYTES</u>			
Sodium (Na+) <small>Method:ISE</small>	138.9	mmol/L	136 - 145
Potassium (K+) <small>Method:ISE</small>	4.1	mmol/L	3.5 - 5.1
Chloride(Cl-) <small>Method:ISE</small>	98.9	mmol/L	98 - 107
Serum			

Comments

The electrolyte panel is ordered to identify electrolyte, fluid, or pH imbalance. Electrolyte concentrations are evaluated to assist in investigating conditions that cause electrolyte imbalances such as dehydration, kidney disease, lung diseases, or heart conditions. Repeat testing of the electrolyte or its components may be used to monitor the patient's response to treatment of any condition that may be causing the electrolyte, fluid or pH imbalance.

----- End Of Report -----

Test done from collected sample.

This is an electronically authenticated report.



Approved by: Dr. Swati Shah

M.B.D.C.P.
G-5456

Page 15 of 15

Generated On : 25-Nov-2023 17:04

Approved On: 25-Nov-2023 10:21